NewcelX has signed a strategic cooperation agreement with the pharmaceutical company Eledon Pharmaceuticals[1]. The goal of this collaboration is to support the NCEL-101 development program aimed at the treatment of type 1 diabetes[1]. The deal was announced on March 9, 2026[1]. The NCEL-101 program represents a joint research project of both partners. This collaboration brings together the expertise of both companies in the field of developing new therapies. Specific details about the scope of cooperation and other terms of the agreement are not mentioned in the available article.